Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For the first time in humans, a chemotherapy drug reaches the brain.

2.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

3.

FDA Expands Durvalumab Label to Operable Lung Cancer

4.

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

5.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot